Literature DB >> 24095059

Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2.

Christian Jost1, Johannes Schilling, Rastislav Tamaskovic, Martin Schwill, Annemarie Honegger, Andreas Plückthun.   

Abstract

Human epidermal growth factor receptor-2 (HER2) is a receptor tyrosine kinase directly linked to the growth of malignancies from various origins and a validated target for monoclonal antibodies and kinase inhibitors. Utilizing a new approach with designed ankyrin repeat proteins (DARPins) as alternative binders, we show that binding of two DARPins connected by a short linker, one targeting extracellular subdomain I and the other subdomain IV, causes much stronger cytotoxic effects on the HER2-addicted breast cancer cell line BT474, surpassing the therapeutic antibody trastuzumab. We determined crystal structures of these DARPins in complex with the respective subdomains. Detailed models of the full-length receptor, constrained by its rigid domain structures and its membrane anchoring, explain how the bispecific DARPins connect two membrane-bound HER2 molecules, distorting them such that they cannot form signaling-competent dimers with any EGFR family member, preventing any kinase dimerization, and thus leading to a complete loss of signaling.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24095059     DOI: 10.1016/j.str.2013.08.020

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  46 in total

1.  Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions.

Authors:  Christian Jost; Jakob C Stüber; Annemarie Honegger; Yufan Wu; Alexander Batyuk; Andreas Plückthun
Journal:  Protein Sci       Date:  2017-07-05       Impact factor: 6.725

2.  FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells.

Authors:  Carole Seguin-Devaux; Jean-Marc Plesseria; Charlène Verschueren; Cécile Masquelier; Gilles Iserentant; Marie Fullana; Mihály Józsi; Jacques H M Cohen; Xavier Dervillez
Journal:  Mol Oncol       Date:  2019-09-30       Impact factor: 6.603

3.  Fab-based bispecific antibody formats with robust biophysical properties and biological activity.

Authors:  Xiufeng Wu; Arlene J Sereno; Flora Huang; Steven M Lewis; Ricky L Lieu; Caroline Weldon; Carina Torres; Cody Fine; Micheal A Batt; Jonathan R Fitchett; Andrew L Glasebrook; Brian Kuhlman; Stephen J Demarest
Journal:  MAbs       Date:  2015       Impact factor: 5.857

4.  Development of a novel anti-HER2 scFv by ribosome display and in silico evaluation of its 3D structure and interaction with HER2, alone and after fusion to LAMP2B.

Authors:  Fatemeh Salimi; Mehdi Forouzandeh Moghadam; Masoumeh Rajabibazl
Journal:  Mol Biol Rep       Date:  2018-09-17       Impact factor: 2.316

5.  Targeting of the epidermal growth factor receptor with mesoporphyrin IX-peptide conjugates.

Authors:  Krystal R Fontenot; Benson G Ongarora; Logan E LeBlanc; Zehua Zhou; Seetharama D Jois; M Graça H Vicente
Journal:  J Porphyr Phthalocyanines       Date:  2016-01       Impact factor: 1.811

6.  Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.

Authors:  Martin Schwill; Rastislav Tamaskovic; Aaron S Gajadhar; Florian Kast; Forest M White; Andreas Plückthun
Journal:  Sci Signal       Date:  2019-01-22       Impact factor: 8.192

Review 7.  Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.

Authors:  Xiaowen Yu; Yu-Ping Yang; Emre Dikici; Sapna K Deo; Sylvia Daunert
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2017-03-24       Impact factor: 10.745

8.  Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells.

Authors:  Elizabeth Siegler; Si Li; Yu Jeong Kim; Pin Wang
Journal:  Hum Gene Ther       Date:  2017-06-22       Impact factor: 5.695

9.  Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.

Authors:  Ashwini Balakrishnan; Anusha Rajan; Alexander I Salter; Paula L Kosasih; Qian Wu; Jenna Voutsinas; Michael C Jensen; Andreas Plückthun; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2019-09-23       Impact factor: 12.531

10.  Peptide ligands for targeting the extracellular domain of EGFR: Comparison between linear and cyclic peptides.

Authors:  Tyrslai M Williams; Rushikesh Sable; Sitanshu Singh; Maria Graca H Vicente; Seetharama D Jois
Journal:  Chem Biol Drug Des       Date:  2017-11-16       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.